
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences is poised to experience significant growth with their promising gene therapy, SGT-003, which has shown lower risk of side effects and potential to become a best-in-class treatment for DMD. The company also has other promising programs for rare diseases, such as Friedreich's ataxia and catecholaminergic polymorphic ventricular tachycardia, highlighting a high unmet need and potential for revenue and market opportunities. With a strong financial update and projected net loss, Solid Biosciences is well-positioned for future success in the life sciences industry.
Bears say
Solid Biosciences is a platform-enabled therapeutics company with a concentrated focus on gene therapy treatments for a variety of neuromuscular and cardiac diseases. The current outlook is negative as the company has not yet achieved any significant clinical or commercial success and faces competition and regulatory risks. Additionally, while the potential for positive outcomes in upcoming data readouts exists, there is also a significant potential for adverse events and setbacks in the clinical development process. With a current valuation that may not fully reflect these risks, the potential for a significant increase in stock price is limited.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares